Physician profile
Asmita C Joshi
NPI 1316994353
$1,192.20
in general payments reported to CMS, 2019-2025
15 companies · $321 in 2025
The $321 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $150 · 2020: $34.35 · 2021: $149 · 2022: $52.89 · 2023: $213 · 2024: $271 · 2025: $321.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $726 · Education: $79.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $725.86 |
| Education | $79.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $331.63 | 2019-2025 | Airsupra, Farxiga |
| Novo Nordisk INC | $223.09 | 2019-2025 | Ozempic, Rybelsus |
| Astellas Pharma US INC | $161.66 | 2023-2025 | Veozah |
| Lilly USA, LLC | $110.95 | 2021-2025 | Mounjaro, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $88.41 | 2023-2024 | |
| Allergan, INC. | $74.08 | 2019 | |
| Amgen INC. | $59.53 | 2022-2024 | Repatha, Otezla |
| Kowa Pharmaceuticals America, INC. | $28.01 | 2025 | Zoryve |
| Abbott Laboratories | $23.85 | 2023 | Freestyle Libre 2 |
| Arbor Pharmaceuticals, INC. | $22.60 | 2021 | |
| Merck Sharp & Dohme LLC | $14.99 | 2019 | |
| Shield Therapeutics INC | $14.83 | 2024 | |
| Biohaven Pharmaceuticals, INC. | $13.36 | 2021 | |
| Glaxosmithkline, LLC. | $13.11 | 2024 | Trelegy Ellipta |
| Abbvie INC. | $12.10 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Asmita Joshi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.